FIGNL1

Across TCGA pan-cancer cohorts, FIGNL1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FIGNL1 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher FIGNL1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FIGNL1 expression acts as an unfavorable survival marker, although some lineages such as COAD and UCEC show a favorable association.

LIHC, LUAD, and COAD are the cancer types where FIGNL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.034	0.554	<.001	6	view →
LUAD	OS	Median	All	0.275	0.675	.005	6	view →
COAD	DFS	Median	II,III,IV	1.000	0.462	.015	6	view →
UCEC	DFS	Median	All	0.964	0.626	.020	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FIGNL1–LIHC (DFS)

Open the LIHC breakdown →